LW402 + methotrexate

LW402 + methotrexate is a combination drug regimen under investigation for the treatment of adults with active rheumatoid arthritis. **Methotrexate** is a well-established antimetabolite and folate antagonist that inhibits several enzymes necessary for nucleotide synthesis, resulting in anti-inflammatory and anti-neoplastic effects. It is a standard treatment for rheumatoid arthritis and related autoimmune and neoplastic disorders. **LW402** is an investigational oral small molecule, being studied specifically in combination with methotrexate, for its potential to improve disease outcomes in moderately to severely active rheumatoid arthritis patients who have been on stable methotrexate doses[5]. The precise mechanism of action of LW402 has not been disclosed in public sources, but clinical trials are focused on its use as an adjunct to methotrexate therapy. The combination is administered orally.

Other names

LW402 + methotrexate